发明名称 |
HMG-COA REDUCTASE INHIBITORS AND METHOD |
摘要 |
<p>Compounds are provided having the following structure and pharmaceutically acceptable salts thereof, wherein R<SUB>1</SUB>, R<SUB>2</SUB>, R<SUB>3</SUB>, R<SUB>4</SUB>, U, V, W, Y, and n are as defined above, which compounds are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis and may be employed as hormone replacement therapy. A method for treating the above diseases employing the above compounds is also provided.</p> |
申请公布号 |
EP1684754(A1) |
申请公布日期 |
2006.08.02 |
申请号 |
EP20040811719 |
申请日期 |
2004.11.19 |
申请人 |
BRISTOL-MYERS SQUIBB COMPANY |
发明人 |
O'CONNOR, STEPHEN P.;ROBL, JEFFREY;AHMAD, SALEEM;BISAHA, SHARON;MURUGESAN, NATESAN;NGU, KHEHYONG;SHI, YAN;STEIN, PHILIP D.;SOUNDARARAJAN, NACHIMUTHU;NATALIE, KENNETH J. JR.;KOLLA, LAXMA R.;SAUSKER, JUSTIN;QUINLAN, SANDRA L.;FAN, JUNYING;PETSCH, DEJAH;GUO, ZHENRONG |
分类号 |
A61K31/435;A61K31/4745;A61K31/505;C07D211/76;C07D213/80;C07D401/14;C07D471/02;C07D471/04;C07D491/04;C07D498/04;C07D513/04 |
主分类号 |
A61K31/435 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|